fusion lung adenosquamous carcinoma patient with short-term clinical benefit after crizotinib treatment: a case report.

rearrangements are validated drivers in non-small cell lung cancer (NSCLC), and occur at an extremely low rate in rare pathological subtypes such as adenosquamous carcinoma (ASC). Crizotinib is known to be effective in patients with -rearranged NSCLC. However, the efficacy of crizotinib in patients with -rearranged lung ASC is unknown. Here, we report the case of a 43-year-old female never-smoker who presented with dry cough for 3 months. The patient was then diagnosed with stage IIIA poorly-differentiated lung ASC with rearrangement (). Programmed death-ligand 1 (PD-L1) expression was high with 50% in tumor cells of her lung puncture biopsy sample. The patient received albumin-bound paclitaxel and camrelizumab as the first-line treatment and achieved a stable disease (SD) response with progression-free survival (PFS) of 2 months. Subsequently, the patient received crizotinib as the second-line treatment and achieved a partial response (PR) with PFS of 4 months. No gene mutation other than (C6:R34) rearrangement was detected from the lung biopsy sample after crizotinib resistance using a panel covering 520 cancer-related genes. We speculate that crizotinib may have a short duration of efficacy against lung ASC. This is the first case report of response to crizotinib for a lung ASC patient with fusion, and may help future targeted therapy investigations and prognostic evaluation for patients with rare pathological subtypes of NSCLC.